Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7624)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 28, 2015 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i9/1184.htm |
| Number | Citing Articles |
| 1 |
Peter R. Galle, Francesco Tovoli, Friedrich Foerster, Marcus A. Wörns, Alessandro Cucchetti, Luigi Bolondi. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017; 67(1): 173 doi: 10.1016/j.jhep.2017.03.007
|
| 2 |
Mutlay Sayan, Nikhil Yegya-Raman, Stephanie H. Greco, Bin Gui, Andrew Zhang, Anupama Chundury, Miral S. Grandhi, Howard S. Hochster, Timothy J. Kennedy, Russell C. Langan, Usha Malhotra, Vinod K. Rustgi, Mihir M. Shah, Kristen R. Spencer, Darren R. Carpizo, John L. Nosher, Salma K. Jabbour. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00345
|
| 3 |
Hussam Hijazi, Marie-Pierre Campeau, David Roberge, David Donath, Real Lapointe, Franck Vandenbroucke-Menu, Daniel Taussky, Karim Boudam, Gabriel Chan, Alexis Bujold, Guila Delouya. Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience. Cureus 2016; doi: 10.7759/cureus.935
|
| 4 |
Lior Charach, Lior Zusmanovitch, Gideon Charach. Hepatocellular Carcinoma. Part 2: Clinical Presentation and Diagnosis. EMJ Hepatology 2017; : 81 doi: 10.33590/emjhepatol/10311703
|
| 5 |
Neal Bhutiani, Prejesh Philips, Charles R. Scoggins, Kelly M. McMasters, Melissa H. Potts, Robert C.G. Martin. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB 2016; 18(7): 593 doi: 10.1016/j.hpb.2016.03.609
|
| 6 |
Masatoshi Kudo. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers 2021; 13(21): 5475 doi: 10.3390/cancers13215475
|
| 7 |
Xi-Zhen Chen, Wei Kevin Zhang, He-Bin Tang, Xiao-Jun Li, Gui-Hua Tian, Hong-Cai Shang, Yu-Sang Li. The Ethanol Supernatant Extracts of Liushenwan Could Alleviate Nanodiethylnitrosamine-Induced Liver Cancer in Mice. Canadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/6934809
|
| 8 |
Eric A. Wang, Jeff P. Stein, Ross J. Bellavia, Scott R. Broadwell. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. International Journal of Clinical Practice 2017; 71(11): e12972 doi: 10.1111/ijcp.12972
|
| 9 |
Qunfang Zhou, Fei Tuo, Ruixia Li, Xiaohui Wang, Juncheng Wang, Zhimei Huang, Minshan Chen, Jinhua Huang. Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.578763
|
| 10 |
Qizheng Dai, Bo Cao, Shiqing Zhao, Aili Zhang. Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future. Bioengineering 2022; 9(9): 474 doi: 10.3390/bioengineering9090474
|
| 11 |
Bruna Scaggiante, Rosella Farra, Barbara Dapas, Gabriele Baj, Gabriele Pozzato, Mario Grassi, Fabrizio Zanconati, Gabriele Grassi. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects. International Journal of Pharmaceutics 2016; 506(1-2): 268 doi: 10.1016/j.ijpharm.2016.04.031
|
| 12 |
|
| 13 |
Matteo Renzulli, Francesco Tovoli, Alfredo Clemente, Anna Maria Ierardi, Irene Pettinari, Giuliano Peta, Giovanni Marasco, Davide Festi, Fabio Piscaglia, Salvatore Cappabianca, Gianpaolo Carrafiello, Rita Golfieri. Ablation for hepatocellular carcinoma: beyond the standard indications. Medical Oncology 2020; 37(4) doi: 10.1007/s12032-020-01348-y
|
| 14 |
Jason K. Wong, Howard J. Lim, Vincent C. Tam, Kelly W. Burak, Laura A. Dawson, Prosanto Chaudhury, Robert J. Abraham, Brandon M. Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maja Segedi, David M. Liu. Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treatment Reviews 2023; 115: 102526 doi: 10.1016/j.ctrv.2023.102526
|
| 15 |
Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun-Ming Rau, Masafumi Ikeda, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, David W. McIlwain, Reigetsu Yoshikawa, Kenichi Nakamura, Kun Liang, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021; 10(5): 451 doi: 10.1159/000516605
|
| 16 |
Jian-Jun Gao, Zhen-Yan Shi, Ju-Feng Xia, Yoshinori Inagaki, Wei Tang. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World Journal of Gastroenterology 2015; 21(42): 12059-12070 doi: 10.3748/wjg.v21.i42.12059
|
| 17 |
V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan, K. K. Laktionov. BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started. Medical Council 2018; (10): 27 doi: 10.21518/2079-701X-2018-10-27-32
|